Childhood Obesity
Conditions
Keywords
Obesity, GLP1 receptor agonist, MRI Body composition
Brief summary
The goal of this study is to quantify the body composition and organ fat distribution changes with obesity interventions in adolescents with severe obesity. The main question the investigators aim to answer is if there is improvement in organ health with weight loss intervention. The investigators will be comparing the degree of these changes between children being treated with GLP1 receptor agonists in addition to lifestyle changes and those managed with lifestyle changes alone. Participants will undergo MRI body composition at baseline and after 9 months.
Interventions
None listed
Sponsors
Alder Hey Children's NHS Foundation Trust
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
12 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
* Age 12 to \<18 years at the time of enrolment * BMI \>99.6th centile or \>2.67 SDS * Informed consent from parent(s) (or person with parental responsibility) and assent from the child or young person for participants aged less than 16 years (or) * Informed consent from the participant if aged ≥ 16 years.
Exclusion criteria
* Body weight above upper limit of the scanner (\>250 kilograms) * Needs general anaesthesia for the MRI scanning * Any contraindications for MRI- Metal implants/claustrophobia * Previous use of GLP-1 receptor agonist * Refusal to consent or refusal to assent from a competent older adolescent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Liver fat measured using quantitative MRI | From enrollment to 9 months | Change in liver fat content from baseline to follow-up, quantified using MRI-derived proton density fat fraction (PDFF). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes to body composition assessed by MRI | Baseline to 9 months | Change from baseline in Visceral adipose tissue(VAT) and Subcutaneous adipose tissue (VAT) measured in cm2 assessed by quantitative MRI |
| Change in pancreatic fat assessed by MRI. | Baseline to 9 months | Change from baseline in pancreatic fat measured as proton density fat fraction (%) assessed by quantitative MRI. |
| Changes in biochemical parameters-fasting glucose | 9 months | Changes from baseline in fasting glucose measured in mmol/l |
| Changes in biochemical parameters-HbA1C | 9 months | Change from baseline in HbA1C measured in mmol/mol |
Countries
United Kingdom
Contacts
CONTACTAnand Ramakrishnan, MD (Ped), MSc (Diab), PhD endo
CONTACTAnand Ramakrishnan, MBBS, MD, MRCPCH, DipUKMP
Outcome results
None listed